Polar Asset Management Partners Inc. Makes New Investment in The Chemours Company (NYSE:CC)

Polar Asset Management Partners Inc. purchased a new position in The Chemours Company (NYSE:CC - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 141,536 shares of the specialty chemicals company's stock, valued at approximately $2,392,000. Polar Asset Management Partners Inc. owned 0.09% of Chemours as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its position in Chemours by 100.4% in the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after buying an additional 1,119 shares during the period. Aster Capital Management DIFC Ltd bought a new position in Chemours in the 4th quarter worth approximately $48,000. Itau Unibanco Holding S.A. increased its position in Chemours by 39.3% in the 4th quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock worth $60,000 after buying an additional 1,003 shares during the period. KBC Group NV increased its position in shares of Chemours by 38.2% during the fourth quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock valued at $104,000 after purchasing an additional 1,708 shares during the period. Finally, Sterling Capital Management LLC increased its position in shares of Chemours by 54.8% during the fourth quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock valued at $143,000 after purchasing an additional 2,991 shares during the period. 76.26% of the stock is owned by institutional investors.

Chemours Price Performance

NYSE:CC traded up $0.33 during trading hours on Thursday, reaching $10.87. The company had a trading volume of 776,997 shares, compared to its average volume of 2,059,835. The stock has a 50-day moving average of $12.13 and a two-hundred day moving average of $16.15. The Chemours Company has a one year low of $9.33 and a one year high of $27.65. The firm has a market capitalization of $1.63 billion, a PE ratio of 19.10 and a beta of 1.76. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter last year, the company earned $0.32 earnings per share. The business's revenue was up .4% on a year-over-year basis. Analysts forecast that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Dividend Announcement

The business also recently declared a dividend, which will be paid on Monday, June 16th. Shareholders of record on Monday, May 19th will be given a $0.0875 dividend. This represents a yield of 3.17%. The ex-dividend date of this dividend is Friday, May 16th. Chemours's dividend payout ratio (DPR) is 175.00%.

Analyst Ratings Changes

CC has been the topic of a number of research reports. Mizuho set a $15.00 price objective on Chemours in a research report on Tuesday, April 15th. Royal Bank of Canada lowered their price objective on Chemours from $17.00 to $14.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. Truist Financial lowered their price objective on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Barclays lowered their price objective on Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 1st. Finally, UBS Group lowered their price objective on Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $17.56.

Insiders Place Their Bets

In other Chemours news, CFO Shane Hostetter acquired 4,450 shares of Chemours stock in a transaction on Monday, May 19th. The shares were bought at an average price of $11.28 per share, with a total value of $50,196.00. Following the completion of the purchase, the chief financial officer now owns 59,694 shares in the company, valued at $673,348.32. This trade represents a 8.06% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.47% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.